Direct oral anticoagulants (DOACs) are preferred over Vitamin K Antagonists (VKAs) in numerous clinical scenarios, such as preventing thromboembolic events in patients with atrial fibrillation and treating venous thromboembolism.– In contrast, DOACs are contraindicated in patients with mechanical heart valves, valvular AF due to mitral stenosis, and antiphospholipid syndrome.– In patients with left ventricular thrombus (LVT), however, the efficacy and safety of DOACs remain uncertain. LVT is a common complication following an acute myocardial infarction (MI). The incidence of LVT […]